Our previous study focusing on patients with NPM1 and/or FLT3-ITD mutated AML showed that patients with either of these mutations detected in CR1 prior to alloHCT had increased relapse and lower OS [12]. This evidence concerns the gene FLT3 and acute myeloid leukemia.